Inactive Instrument

News Soligenix Inc OTC Bulletin Board

Equities

US8342232084

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Apr. 15	Sector Update: Health Care Stocks Softer Late Afternoon	MT
Apr. 15	Sector Update: Health Care Stocks Gain Monday Afternoon	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Soligenix Announces Pricing of $4.75 Million Public Offering	Apr. 18	PR
Sector Update: Health Care Stocks Softer Late Afternoon	Apr. 15	MT
Sector Update: Health Care Stocks Gain Monday Afternoon	Apr. 15	MT
Soligenix Shares Rise After Active Ingredient in MarVax Gets US FDA's Orphan Drug Designation	Apr. 15	MT
Soligenix Shares Rise After SuVax Gets Orphan Drug Designation from US FDA	Apr. 15	DJ
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection	Apr. 15	PR
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection	Apr. 11	PR
Soligenix Announces Agreement on the Design of Second Confirmatory Placebo-Controlled Trial for Hybryte? with the European Medicines Agency	Apr. 03	CI
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency	Apr. 03	PR
Soligenix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results	Mar. 15	PR
Soligenix Announces Formation of Beh et s Disease Medical Advisory Board	Feb. 09	AQ
Soligenix, Inc. Announces Formation of Behçet's Disease Medical Advisory Board	Feb. 08	CI
Soligenix to Present at The Microcap Conference	Jan. 25	PR
FDA Grants Soligenix 'Fast Track' Designation for Dusquetide in the Treatment of Oral Lesions of Behcet's Disease	Jan. 09	AQ
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	Jan. 08	PR
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease	Jan. 08	CI
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis	Jan. 04	PR
Soligenix Announces Top-Line Results of the Phase 2A Study of Sgx302 (Synthetic Hypericin) in Patients with Mild-To-Moderate Psoriasis	Jan. 04	CI
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses	Jan. 02	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Soligenix Inc OTC Bulletin Board

Equities

US8342232084

Summary

Filters